The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Classifying oligometastasis in non-small cell lung cancer
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, emphasizes the complexity of oligometastasis in non-small cell lung cancer (NSCLC). Precise clinical classification to inform treatment strategies is essential, due to the existence of various subtypes such as de novo, recurrent, and induced oligometastasis, each with their own subcategories. This complexity highlights the importance of accurate classification in designing clinical trials and developing effective treatment approaches. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So just now in the oligometastasis session, we discussed a lot about the clinical classification of the oligometastasis in non-small cell cancer. And I presented the classification. I think this is a very complicated population in terms of the clinical classification. We can see we have three major classifications and then some types of this oligometastasis that are de novo, recurrent and induced oligometastasis...
So just now in the oligometastasis session, we discussed a lot about the clinical classification of the oligometastasis in non-small cell cancer. And I presented the classification. I think this is a very complicated population in terms of the clinical classification. We can see we have three major classifications and then some types of this oligometastasis that are de novo, recurrent and induced oligometastasis. And each classification we still have three subtypes that are oligorecurrence, oligoprogression and oligoresistance. So I think this kind of population is very complicated. So if we design some clinical trial or we consider the treatment strategy, we must do a very precise classification in terms of this complicated population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
